The Cannabidiol (CBD) market is projected to grow substantially through 2034, according to a new analysis from ResearchAndMarkets, but regulatory uncertainty in the United States continues to cloud the industry’s long-term trajectory.
The Numbers
The global CBD market is expected to see compound annual growth rates in the mid-teens through the forecast period. Key drivers include:
- Expanding product formats: CBD is no longer just oils and tinctures. Topicals, edibles, beverages, and skincare products have broadened consumer access.
- Wellness mainstreaming: As consumer attitudes toward cannabis-derived products soften, CBD has positioned itself as the non-intoxicating alternative to THC.
- International markets: Europe and Canada are emerging as meaningful growth markets, with novel food regulations in the EU creating both barriers and opportunities.
The American Problem
Despite the projections, the U.S. CBD industry remains in a regulatory grey zone. The 2018 Farm Bill legalized hemp and hemp-derived CBD at the federal level, but the FDA has yet to establish clear regulatory pathways for CBD in food, beverages, and dietary supplements.
Without FDA clarity:
- Big-box retail adoption remains limited: Major retailers cite regulatory risk as a barrier to stocking CBD products at scale.
- Health claims remain problematic: Companies must tread carefully around disease-state claims, limiting marketing effectiveness.
- Quality inconsistency persists: The absence of Good Manufacturing Practice (GMP) requirements specific to CBD creates consumer confidence issues.
The recent change in DEA scheduling posture — with cannabis rescheduling to Schedule III under consideration — could indirectly benefit CBD by creating a more rational federal framework for cannabis-derived compounds broadly.
Hemp-Derived Intoxicants: A Growing Threat
A subtler threat to the CBD market comes from the rise of hemp-derived intoxicating cannabinoids (HDICs), including delta-8 THC and similar compounds. These products occupy a legal grey zone and are often marketed as alternatives to both CBD and traditional THC products. Their growth could cannibalize CBD’s wellness positioning without adding to industry revenues.
Regional Dynamics
United States: Largest single market by revenue, but constrained by regulatory ambiguity. State-level markets vary dramatically in maturity and competitiveness.
Europe: The EU Novel Food process has created barriers to entry for some CBD products, but the bloc’s large consumer base makes it strategically important. UK post-Brexit regulations add complexity.
Canada: A smaller but more clearly regulated market. Canadian consumers have broader access to CBD products through licensed dispensaries, though market size is limited compared to the U.S.
Investment Takeaways
For cannabis investors evaluating CBD-focused companies:
- Scale matters: Companies with proprietary extraction, established retail relationships, and diversified product lines are better positioned than pure-play CBD startups.
- Regulatory moats: Companies with FDA engagement strategies or existing GRAS (Generally Recognized As Safe) designations may have competitive advantages as the regulatory landscape clarifies.
- International optionality: European market access, particularly through novel food approvals, could provide meaningful revenue diversification.
The CBD market’s projected growth reflects genuine consumer demand. The gap between potential and realized value, however, remains enormous — and that gap will only close with regulatory clarity that may still be years away.